癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具，可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分，识别结合到自噬通路中的蛋白是非常重要的，便于让我们理解自噬在正常生理、病理过程中的作用，如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。
Anti-CD47 (Extracellular region) Antibody
- 产品详情
- 实验流程
- 背景知识
Application 
| ICC, IP |
|---|---|
| Primary Accession | Q08722 |
| Host | Mouse |
| Clonality | Mouse Monoclonal |
| Isotype | IgG1 |
| Clone Names | M054 |
| Calculated MW | 35214 Da |
| Gene ID | 961 |
|---|---|
| Other Names | Antigenic surface determinant protein OA3, Integrin-associated protein, IAP, Leukocyte surface antigen CD47, MER6 |
| Target/Specificity | CD47 is a five-pass transmembrane protein expressed on all normal cells, as well as in cancer cells. CD47 is used by macrophages to distinguish between "self" and "non-self" cells. SIRPα expressed on myeloid cells including macrophages, and neuronal cells in the central nervous system, can bind CD47. SIRPα cytoplasmic tail can inhibit macrophage phagocytosis towards CD47-expressing cells. Thus, the CD47/SIRPα pahtway serves as an innate immune checkpoint. Additionally, CD47 was reported to modulate lymphocyte cell activation and proliferation. CD47 is over-expressed in many types of cancer, and the expression level of CD47 on cancer cells is negatively associated with cancer survival. Monoclonal antibody therapies that can block CD47-SIRPα interaction are being actively pursued for clinical applications. In addition to SIRPα, CD47 interacts with thrombospondin-1, VEGFR2, FAS, and certain integrins in different contexts, and influences their downstream signaling. |
| Dilution | ICC~~N/A IP~~N/A |
| Format | Protein G Purified |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | Anti-CD47 (Extracellular region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Shipping | Blue Ice |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
CD47 is a five-pass transmembrane protein expressed on all normal cells, as well as in cancer cells. CD47 is used by macrophages to distinguish between "self" and "non-self" cells. SIRPα expressed on myeloid cells including macrophages, and neuronal cells in the central nervous system, can bind CD47. SIRPα cytoplasmic tail can inhibit macrophage phagocytosis towards CD47-expressing cells. Thus, the CD47/SIRPα pahtway serves as an innate immune checkpoint. Additionally, CD47 was reported to modulate lymphocyte cell activation and proliferation. CD47 is over-expressed in many types of cancer, and the expression level of CD47 on cancer cells is negatively associated with cancer survival. Monoclonal antibody therapies that can block CD47-SIRPα interaction are being actively pursued for clinical applications. In addition to SIRPα, CD47 interacts with thrombospondin-1, VEGFR2, FAS, and certain integrins in different contexts, and influences their downstream signaling.
终于等到您。ABCEPTA（百远生物）抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息，您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问，联系：0512-88856768 tech-china@abcepta.com.
